DGAP-News: NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

 | Source: EQS Group AG EQS Group AG 

DGAP-News: Neovacs S.A. / Key word(s): Conference
NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

19.01.2015 / 18:30

---------------------------------------------------------------------

PRESS RELEASE

NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

 
Paris,  January 19, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, announced
today that the Company will be presenting at the BIO CEO & Investor
Conference to be held in New York on February 9-10, 2015.

The 17th Annual BIO CEO & Investor Conference attracts over 750 investors
and takes place at the Waldorf Astoria, New York. A select number of
biotech CEOs are given the opportunity to introduce their companies,
technology and development programs.

Miguel Sieler, CEO of Neovacs, will present on February 9, 2015 at 9:30 am
E.T.

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts 

NEOVACS       

Nathalie Trépo       
+33 (0)1 53 10 93 00   
ntrepo@neovacs.com

Press - Financial Communications- Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35           stéphanie.tabouis@consultants.publicis.fr  

Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
Raimund.Gabriel@mc-services.eu

Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023           
msollid@theruthgroup.com



---------------------------------------------------------------------

19.01.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                             
Company:     Neovacs S.A.                                        
             3-5, Impasse Reille                                 
             75014 Paris                                         
             France                                              
Phone:       +33 (0)1 53 10 93 00                                
Fax:         +33 (0)1 53 10 93 03                                
E-mail:      www.neovacs.fr                                      
Internet:    info@neovacs.fr                                     
ISIN:        FR0004032746                                        
WKN:         A1CVKR                                              
Listed:      Freiverkehr in Stuttgart; Frankfurt in Open Market  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
314653 19.01.2015
GlobeNewswire